Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RUA Life SciencesFRA:AOHA 42 EV-to-EBIT is -67.12 as of Sep. 16, 2026. GuruFocus rates FRA:AOHA with a GF Score™ of 42/100 and a GF Value™ of €0.15 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 478 Medical Devices & Instruments companies, RUA Life Sciences ranks worse than 209204.81% on this metric.
The historical rank and industry rank for RUA Life Sciences's EV-to-EBIT or its related term are showing as below:
FRA:AOHA'
s EV-to-EBIT Range Over the Past 10 Years
Min: -131.44 Med: -3.45 Max: 0.01
Current: -66.48
During the past 13 years, the highest EV-to-EBIT of RUA Life Sciences was 0.01. The lowest was -131.44. And the median was -3.45.
FRA:AOHA's EV-to-EBIT is ranked worse than 100% of 478
companies
in the Medical Devices & Instruments industry
Industry Median: 18.16
vs FRA:AOHA: -66.48
RUA Life Sciences (FRA:AOHA) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
RUA Life Sciences's Enterprise Value for the quarter that ended in Mar. 2026 was €6.96 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RUA Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RUA Life Sciences EV-to-EBIT Related Terms
RUA Life Sciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, RUA Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's EV-to-EBIT falls into.
RUA Life Sciences's current Enterprise Value is €18.73 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RUA Life Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RUA Life Sciences (FRA:AOHA) has a EV-to-EBIT of -67.12 as of Sep. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on RUA Life Sciences and its competitors. According to the industry distribution chart, RUA Life Sciences ranks #999999 out of 478 companies in the Medical Devices & Instruments industry.
Is RUA Life Sciences' EV-to-EBIT too high?
RUA Life Sciences' current EV-to-EBIT is -67.12. Based on the distribution chart, RUA Life Sciences ranks #999999 out of 478 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, RUA Life Sciences has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, RUA Life Sciences ranks #999999 out of 478 companies for EV-to-EBIT. This places RUA Life Sciences in the lower half of its industry. The industry median EV-to-EBIT is 18.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.16, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on RUA Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RUA Life Sciences's current EV-to-EBIT is -67.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (FRA:AOHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.15, compared to a current price of €0.29 — trading 96% above its estimated fair value. The current EV-to-EBIT is -67.12. RUA Life Sciences' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For RUA Life Sciences (FRA:AOHA), the current EV-to-EBIT is -67.12 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (FRA:AOHA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of €0.29 is trading 96% above its estimated GF Value™ of €0.15.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:AOHA:
EV-to-EBIT: -67.12
GF Value™: €0.15 vs. price of €0.29 (96% above fair value)
No single metric tells the full story. See the FRA:AOHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
42GF Score
Get the complete analysis for FRA:AOHA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AOHA has been successfully added to your 
